Dr. Kantoff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021
Summary
- Dr. Philip Kantoff is the CEO and Co-Founder of Convergent Therapeutics in Cambridge, Massachusetts. He is a medical oncologist and former Chair of the Department of Medicine at Memorial Sloan-Kettering Cancer Center. He is also the Jerome and Nancy Kohlberg Chair Emeritus at Harvard Medical School. He received his medical degree from The Warren Alpert Medical School of Brown University, his residency at NYU-Bellevue in New York and his fellowship in medical oncology at the Dana-Farber Cancer Institute.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1987 - 1989
NYU Grossman School of MedicineResidency, Internal Medicine, 1979 - 1983
The Warren Alpert Medical School of Brown UniversityClass of 1979
Certifications & Licensure
MA State Medical License 1987 - 2025
NY State Medical License 1979 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- Boston Magazine Castle Connolly, 2008-2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Publications & Presentations
PubMed
- 1131 citationsExome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerChristopher E. Barbieri, Sylvan C. Baca, Michael S. Lawrence, Francesca Demichelis, Mirjam Blattner
Nature Genetics. 2012-06-01 - 803 citationsIntegrative clinical genomics of advanced prostate cancer.Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro
Cell. 2015-05-21 - 776 citationsGenomic correlates of clinical outcome in advanced prostate cancer.Wassim Abida, Joanna Cyrta, Glenn Heller, Davide Prandi, Joshua Armenia
Proceedings of the National Academy of Sciences of the United States of America. 2019-06-04
Journal Articles
- Association of Genetic Variation of the Six Gene Prognostic Model for Castration‐Resistant Prostate Cancer with SurvivalMark M Pomerantz, Philip W Kantoff, The Prostate
- A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate CancerChristopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate
Lectures
- 16th Biennial Urologic Cancer CourseHarvard Medical School, Boston, Massachusetts - 10/11/2012
Other
- Clinical presentation and diagnosis of prostate cancerKantoff PW, Smith JA, Taplin M
http://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-02-05 - Initial staging and evaluation of men with newly diagnosed prostate cancerKantoff PW, Smith JA, Taplin M
http://www.uptodate.com/contents/initial-staging-and-evaluation-of-men-with-newly-diagnosed-prostate
UpToDate, Wolters Kluwer Health - 2013-02-05 - Initial risk-stratified treatment for advanced testicular germ cell tumorsKantoff PW, Gilligan TD
http://www.uptodate.com/contents/initial-risk-stratified-treatment-for-advanced-testicular-germ-cell
UpToDate, Wolters Kluwer Health - 2012-09-17 - Join now to see all
Authored Content
- Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-Resistant Prostate Cancer in the Era of Precision OncologyApril 2018
Press Mentions
Rana R. McKay, MD: Developing Clinical Trials to Answer Questions Raised in PracticeApril 20th, 2022- POINT Biopharma Global : Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-Α (Rosopatamab-225Ac) in Combination with PNT2002 for Progressive mCRPCSeptember 14th, 2021
- Ziopharm Finds New CEO After Six-Month Search; CFO Transition at Lonza to Take Place in DecemberSeptember 3rd, 2021
- Join now to see all
Grant Support
- Df/Hcc Spore In Prostate CancerNational Cancer Institute2007–2011
- Developmental Research ProgramNational Cancer Institute2007–2011
- Career Development ProgramNational Cancer Institute2007–2011
- Administration, Evaluation, And Planning CoreNational Cancer Institute2007–2011
- Molecular Signatures Of Lethal An Indolent Prostate CancerNational Cancer Institute2007–2009
- Spore In Prostate CancerNational Cancer Institute2002–2006
- Developmental Projects ProgramNational Cancer Institute2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
